Key facts
- CorVista Health’s last known valuation is $170.0M (Dec 2020).
- It has raised $103.4M; the latest was Later Stage VC ($1.1M) in Oct 2025.
- Notable investors include Ambix Venture Management, Ambix Ventures, Arrize Capital, MedVenture Partners (Japan).
- CorVista Health has filed 1 Form D with the SEC, most recently Apr 2023 ( sold).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for CorVista Health
- ·The full record, as it builds
Funding rounds
No funding rounds for CorVista Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CorVista Health
Developer of a cardiac diagnostic platform designed to transform the way cardiovascular diseases are diagnosed. The company uses disciplines of advanced mathematics and physics, artificial intelligence, and cloud computing to develop a novel, radiation-free, and exercise-free cardiac diagnostic technology that uses a portable device, needing only WiFi or cellular signal, and can be performed in a doctor's office, satellite clinic, nursing home, or mobile setting, enabling physicians to evaluate heart function without radiation, contrast agents, injections, fasting or exercise.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2012
- Employees
- 25
- Website
- corvista.com/
- Ownership
- Privately Held (backing)
CorVista Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CorVista Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CorVista Health in its N-PORT filings yet. We sweep new filings monthly.